Cargando…

Fluorescent PLGA Nanocarriers for Pulmonary Administration: Influence of the Surface Charge

Nearly four million yearly deaths can be attributed to respiratory diseases, prompting a huge worldwide health emergency. Additionally, the COVID-19 pandemic’s death toll has surpassed six million, significantly increasing respiratory disease morbidity and mortality rates. Despite recent advances, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Areny-Balagueró, Aina, Mekseriwattana, Wid, Camprubí-Rimblas, Marta, Stephany, Andrea, Roldan, Ariana, Solé-Porta, Anna, Artigas, Antonio, Closa, Daniel, Roig, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322090/
https://www.ncbi.nlm.nih.gov/pubmed/35890341
http://dx.doi.org/10.3390/pharmaceutics14071447
_version_ 1784756211671891968
author Areny-Balagueró, Aina
Mekseriwattana, Wid
Camprubí-Rimblas, Marta
Stephany, Andrea
Roldan, Ariana
Solé-Porta, Anna
Artigas, Antonio
Closa, Daniel
Roig, Anna
author_facet Areny-Balagueró, Aina
Mekseriwattana, Wid
Camprubí-Rimblas, Marta
Stephany, Andrea
Roldan, Ariana
Solé-Porta, Anna
Artigas, Antonio
Closa, Daniel
Roig, Anna
author_sort Areny-Balagueró, Aina
collection PubMed
description Nearly four million yearly deaths can be attributed to respiratory diseases, prompting a huge worldwide health emergency. Additionally, the COVID-19 pandemic’s death toll has surpassed six million, significantly increasing respiratory disease morbidity and mortality rates. Despite recent advances, it is still challenging for many drugs to be homogeneously distributed throughout the lungs, and specifically to reach the lower respiratory tract with an accurate sustained dose and minimal systemic side effects. Engineered nanocarriers can provide increased therapeutic efficacy while lessening potential biochemical adverse reactions. Poly(lactic-co-glycolic acid) (PLGA), a biodegradable polymer, has attracted significant interest as an inhalable drug delivery system. However, the influence of the nanocarrier surface charge and its intratracheal instillation has not been addressed so far. In this study, we fabricated red fluorescent PLGA nanocapsules (NCs)—Cy5/PLGA—with either positive (Cy5/PLGA+) or negative surface charge (Cy5/PLGA-). We report here on their excellent colloidal stability in culture and biological media, and after cryo-storage. Their lack of cytotoxicity in two relevant lung cell types, even for concentrations as high as 10 mg/mL, is also reported. More importantly, differences in the NCs’ cell uptake rates and internalization capacity were identified. The uptake of the anionic system was faster and in much higher amounts—10-fold and 2.5-fold in macrophages and epithelial alveolar cells, respectively. The in vivo study demonstrated that anionic PLGA NCs were retained in all lung lobules after 1 h of being intratracheally instilled, and were found to accumulate in lung macrophages after 24 h, making those nanocarriers especially suitable as a pulmonary immunomodulatory delivery system with a marked translational character.
format Online
Article
Text
id pubmed-9322090
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93220902022-07-27 Fluorescent PLGA Nanocarriers for Pulmonary Administration: Influence of the Surface Charge Areny-Balagueró, Aina Mekseriwattana, Wid Camprubí-Rimblas, Marta Stephany, Andrea Roldan, Ariana Solé-Porta, Anna Artigas, Antonio Closa, Daniel Roig, Anna Pharmaceutics Article Nearly four million yearly deaths can be attributed to respiratory diseases, prompting a huge worldwide health emergency. Additionally, the COVID-19 pandemic’s death toll has surpassed six million, significantly increasing respiratory disease morbidity and mortality rates. Despite recent advances, it is still challenging for many drugs to be homogeneously distributed throughout the lungs, and specifically to reach the lower respiratory tract with an accurate sustained dose and minimal systemic side effects. Engineered nanocarriers can provide increased therapeutic efficacy while lessening potential biochemical adverse reactions. Poly(lactic-co-glycolic acid) (PLGA), a biodegradable polymer, has attracted significant interest as an inhalable drug delivery system. However, the influence of the nanocarrier surface charge and its intratracheal instillation has not been addressed so far. In this study, we fabricated red fluorescent PLGA nanocapsules (NCs)—Cy5/PLGA—with either positive (Cy5/PLGA+) or negative surface charge (Cy5/PLGA-). We report here on their excellent colloidal stability in culture and biological media, and after cryo-storage. Their lack of cytotoxicity in two relevant lung cell types, even for concentrations as high as 10 mg/mL, is also reported. More importantly, differences in the NCs’ cell uptake rates and internalization capacity were identified. The uptake of the anionic system was faster and in much higher amounts—10-fold and 2.5-fold in macrophages and epithelial alveolar cells, respectively. The in vivo study demonstrated that anionic PLGA NCs were retained in all lung lobules after 1 h of being intratracheally instilled, and were found to accumulate in lung macrophages after 24 h, making those nanocarriers especially suitable as a pulmonary immunomodulatory delivery system with a marked translational character. MDPI 2022-07-11 /pmc/articles/PMC9322090/ /pubmed/35890341 http://dx.doi.org/10.3390/pharmaceutics14071447 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Areny-Balagueró, Aina
Mekseriwattana, Wid
Camprubí-Rimblas, Marta
Stephany, Andrea
Roldan, Ariana
Solé-Porta, Anna
Artigas, Antonio
Closa, Daniel
Roig, Anna
Fluorescent PLGA Nanocarriers for Pulmonary Administration: Influence of the Surface Charge
title Fluorescent PLGA Nanocarriers for Pulmonary Administration: Influence of the Surface Charge
title_full Fluorescent PLGA Nanocarriers for Pulmonary Administration: Influence of the Surface Charge
title_fullStr Fluorescent PLGA Nanocarriers for Pulmonary Administration: Influence of the Surface Charge
title_full_unstemmed Fluorescent PLGA Nanocarriers for Pulmonary Administration: Influence of the Surface Charge
title_short Fluorescent PLGA Nanocarriers for Pulmonary Administration: Influence of the Surface Charge
title_sort fluorescent plga nanocarriers for pulmonary administration: influence of the surface charge
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322090/
https://www.ncbi.nlm.nih.gov/pubmed/35890341
http://dx.doi.org/10.3390/pharmaceutics14071447
work_keys_str_mv AT arenybalagueroaina fluorescentplgananocarriersforpulmonaryadministrationinfluenceofthesurfacecharge
AT mekseriwattanawid fluorescentplgananocarriersforpulmonaryadministrationinfluenceofthesurfacecharge
AT camprubirimblasmarta fluorescentplgananocarriersforpulmonaryadministrationinfluenceofthesurfacecharge
AT stephanyandrea fluorescentplgananocarriersforpulmonaryadministrationinfluenceofthesurfacecharge
AT roldanariana fluorescentplgananocarriersforpulmonaryadministrationinfluenceofthesurfacecharge
AT soleportaanna fluorescentplgananocarriersforpulmonaryadministrationinfluenceofthesurfacecharge
AT artigasantonio fluorescentplgananocarriersforpulmonaryadministrationinfluenceofthesurfacecharge
AT closadaniel fluorescentplgananocarriersforpulmonaryadministrationinfluenceofthesurfacecharge
AT roiganna fluorescentplgananocarriersforpulmonaryadministrationinfluenceofthesurfacecharge